课件：CCB的肾脏保护.ppt

RemuzziBENEDICT1004 * * * * There were no significant differences between the chlorthalidone and amlodipine groups with respect to the incidence of ESRD (RR 1.12; 95% CI, 0.89-1.40). The visionary group did not differ significantly from the chlorthalidone group with respect to ESRD (RR 1.11; 95% CI, 0.88-1.38). The ALLHAT population was selected for high CVD risk; mean baseline creatinine was 1.0 mg/dL; more detailed analyses of high–renal-risk subgroups will be forthcoming. SLIDE 57 The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997. In clinical trials, the most common side effects versus placebo were edema (8.3% vs 2.4%), headache (7.3% vs 7.8%), fatigue (4.5% vs 2.8%), and dizziness (3.2% vs 3.4%). Amlodipine besylate is indicated for the treatment of hypertension and angina. Please see full prescribing information enclosed in this slide kit. * Calcium channel blockers have evolved since the first generation of short-acting ones such as …(read some examples) Except for Verapamil and Diltiazem, some short-acting CCB’s, due to their effect of sudden BP reduction, caused reflex tachycardia and the risk for heart attack. They tried to reduce these serious side effects by making slow release formula, but some patients still reacted adversely. A new breed of CCB’s have arrived with molecules which are intrinsically long-acting, Either with a long plasma half life to sustain their effect, or with a long receptor half-life, to sustain their effect on the target vascular tissues. Let me explain more, doctors, regarding the last one. 397(214) 116 98 * * * P值：0.0012 * * 施慧达在肾脏病合并高血压中的应用 作为第三代长效CCB的代表施慧达，在治疗肾脏病合并高血压方面疗效显著 P0.01,n=90 P0.01,n=90 P0.01,n=90 P0.01,n=90 医学创新研究 2008;5(9)